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Abstract 
 
Aims: The treatment of prostate cancer has evolved markedly over the last forty years, 
including radiotherapy, notably with escalated dose and targeting. However, the optimal 
treatment for localised disease has not been established in comparative randomised trials. 
We aim to describe the history of prostate radiotherapy trials, including their QA processes, 
and compare these with the ProtecT trial. 
Materials and methods: The UK ProtecT randomised trial compares external beam 
conformal radiotherapy, surgery and active monitoring for clinically localised prostate cancer 
and will report on the primary outcome (disease-specific mortality) in 2016 following 
recruitment between 1999-2009. The embedded QA programme consisted of on-site 
machine dosimetry at the nine trial centres, a retrospective review of outlining and 
adherence to dose constraints based on the trial protocol in 54 participants (randomly 
selected, around 10% of total randomised to radiotherapy, n = 545). These QA processes 
and results were compared with prostate radiotherapy trials of a comparable era. 
Results: There has been an increasingly sophisticated QA programme in UK prostate 
radiotherapy trials over the last 15 years reflecting dose escalation and treatment 
complexity. In ProtecT, machine dosimetry results were comparable between trial centres 
and with the UK RT01 trial. The outlining review showed that the majority of deviations were 
clinically acceptable although three (1.4%) may have been of clinical significance and were 
related to outlining of the prostate. Seminal vesicle outlining varied, possibly due to several 
prostate trials running concurrently with different protocols. Adherence to dose constraints in 
ProtecT was considered acceptable with 80% of randomised participants having two or less 
deviations and PTV coverage was excellent. 
Conclusion: The ProtecT trial QA results were satisfactory and comparable to trials of its 
era. Future trials should aim to standardise treatment protocols and QA programmes where 
possible to reduce complexities for centres involved in multiple trials. 
Trial registration: ISCTRN 20141297 
 
Research Highlights  
 The optimal treatment for localised prostate cancer has not been established by 
randomised evidence 
 Radiotherapy can be curative for localised disease 
 Trial QA is necessary with increasing radiotherapy dose and complexity 
 ProtecT compares active monitoring, radiotherapy and surgery and reports  in 2016 
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 The ProtecT QA programme was comparable to other UK trials of its era with 
satisfactory results 
 
Introduction 
 
In 2016, the first outcome data from the UK ProtecT trial will be reported. In this landmark 
UK National Institute for Health Research-funded trial, men with clinically localised prostate 
cancer were randomised to radical prostatectomy, external beam radiotherapy, or active 
monitoring [1]. Whether or not there are differences in outcomes between these three 
approaches, there will undoubtedly be an appraisal of the trial’s treatment technique in the 
light of today’s technology, the use of dose escalation in ‘conventional’ 2 Gy fractions and 
the quality assurance data. This is inevitable, given that the ProtecT trial is unique in 
comparing three prostate treatment modalities, probably was only achievable when it was 
done and in the UK – and so will never be repeated. There have been a several other 
landmark trials in the UK of radiotherapy for prostate cancer, including the Medical Research 
Council (MRC) RT01 and PR07 trials, the Cancer Research UK/NIHR Cancer Research 
Network CHHIP trial, and exploratory data from the MRC STAMPEDE trial [2-5]. This article 
aims to put these radiotherapy trials into their historical context as a backdrop when the first 
results of the ProtecT trial are unveiled in 2016. 
 
 
Radiotherapy for prostate cancer; technology shifts 
the goalposts 
 
The first descriptions of radiotherapy for prostate cancer come from the early 1900s, when 
reports of radium needle insertions were published in the Journal of the American Medical 
Association [6]. The advent of external beam radiotherapy during the course of the century 
led to more patients being treated, but a paucity of evidence. Notable from the era in the 
1970’s and early 1980’s were the Stanford case series of Bagshaw, which laid the 
foundations of clinical practice [7]. At that time, conventional radiotherapy planning involved 
a planning cystogram, and the manual definition of radiotherapy fields based - ultimately - on 
the physician’s opinion. The advent of CT planning in the late 1980’s radically changed 
practice, the initial hope being that radiotherapy fields could be made smaller, because the 
tumour definition was more accurate, and so more normal tissue would be spared. In fact, 
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the hope was based on a false premise, though the reasoning was correct. Tumour definition 
was much more precise, but in turn radiotherapy fields often became larger, as it was 
evident, in retrospect, that geographical miss had been more common than was previously 
supposed [8]. 
 
Using CT planning, it was also possible to accurately define the extent of rectum included in 
a high dose volume, even though there was no obvious consensus as to how much rectal 
irradiation was ‘acceptable’. The new level of accuracy, coupled with isocentric planning and 
delivery on linear accelerators rather than on cobalt, also permitted another development - 
conformal radiotherapy. In its early days, this was achieved by the manufacture of 
customised lead blocks, which were mounted on a tray placed on the linear accelerator 
head. It was presumed that this would, by reducing the volume of normal tissue irradiated, 
also reduce radiotherapy side effects, and this was proven in a landmark publication of  the 
first randomised trial comparing conformal and conventional radiotherapy for pelvic tumours 
[9].  
 
Even in the early days of conformal radiotherapy, another goal was envisaged - that of dose 
escalation, based on the philosophy that, if a rate of 5% of grade 3-4 late toxicity was 
“acceptable”, and if conformal radiotherapy reduced this rate, it would permit dose 
escalation, hopefully with improved tumour control, titrated against this “acceptable” level of 
toxicity. Several randomised trials of dose escalation for prostate cancer were opened in the 
1990’s, following pilot studies which suggested that this approach was safe, and these trials 
have now all reported outcome data [2,10-13]. Though dose-escalation is now routine 
practice, it was not state of the art in external beam radiotherapy for prostate cancer at the 
time when the UK ProtecT study was designed in the late 1990’s. Importantly, though 
several clinical centres had the capacity for conformal radiotherapy, it was by no means 
uniformly available across the UK, and even CT planning was not universal at that time.  
 
In the ProtecT trial, patients with clinically organ-confined prostate cancer were to be 
randomised to radical prostatectomy, radical external beam radiotherapy, or active 
monitoring. The problem for the designers of ProtecT in the late 1990s was how to make the 
radiotherapy technique as ‘future-proof’ as possible, against a backdrop of limited or non-
existent evidence of long term efficacy. Too conservative, and in the event of radiotherapy 
turning out to be less effective, the trial would be criticised for under-treating patients. Too 
aggressive, and it would be criticised for over-treating patients. Another factor in the UK was 
the increasing use of neo-adjuvant hormone therapy in combination with radiotherapy and 
whether this was also to be included in the ProtecT trial although this was not standard 
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practice in the USA. Other contrasts existed between the UK and the USA in terms of dose 
escalation; in the US, the dose per fraction was limited to 1.8 Gy and the total dose was 
being escalated to 78 or 80 Gy [14], whilst in the UK, the dose per fraction was 2 Gy and the 
total dose was limited to 74 Gy. The latter technique was employed in the MRC’s RT01 trial 
[2], which recruited between 1998-2001 and randomised patients to a ‘standard’ dose of 64 
Gy in 32 fractions, versus an escalated dose of 74 Gy in 37 fractions. 
 
In the event, the technique chosen for ProtecT was similar to that used for RT01, in that it 
employed (a) neo-adjuvant hormone therapy, and (b) dose escalated radiotherapy to a total 
of 74 Gy in 37 fractions. There were, however, differences between the two trials; although 
the treatment was given in two phases, in RT01 the phase II dose was 10 Gy, whereas in 
ProtecT it was 18 Gy. ProtecT also had organ at risk dose constraints pre-specified, unlike in 
RT01. 
 
The ProtecT trial recruited patients from late 1999 to early 2009, a period when technical 
developments in radiotherapy have continued apace. Firstly, came the development of portal 
imaging - another technology that was far from universal in the UK at the ProtecT trial outset. 
Then, the first reports of Intensity Modulated Radiotherapy (IMRT) for prostate cancer, and 
subsequently the use of Image Guided Radiotherapy (IGRT) led to a growing pressure to 
use these techniques routinely [15,16]. Indeed, the current European Guidelines state that 
the use of IMRT for prostate cancer radiotherapy should now be standard [17]. Conceptually, 
the argument for IMRT is compelling, but does that weaken the conclusions from trials which 
came too early to use it? It could be argued that long term radiotherapy toxicity in trials such 
as RT01 and ProtecT might have been lessened through the use of IMRT, but in a 
comparative setting with other modalities, similar arguments could also be made about the 
evolution of open to robotic prostatectomy. 
 
 
Evidence versus belief; does definitive local therapy 
cure prostate cancer? 
 
Internationally, the immense uncertainties around treatment of localised  prostate cancer 
were the context for the first randomised trials in which one arm was - essentially - no 
treatment. These were studies of radical prostatectomy versus ‘watchful waiting’. The latter 
is a strategy in which treatment is explicitly avoided unless given for symptoms - so by 
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implication it is palliative only. Two such trials have reported mature results: the 
Scandinavian SPCG-4 and the US PIVOT trials. 
 
In SPCG-4, men were diagnosed through clinically apparent, as opposed to PSA screen-
detected disease, and were, therefore, often symptomatic. In that trial, 695 men were 
randomised to radical prostatectomy (n = 347) or watchful waiting (n = 348) with a median 
follow-up of 12 years. Overall, there was a significant disease-specific survival advantage for 
men treated with surgery, but a more recent analysis has indicated that this benefit was 
greatest for men either 65 years old or younger or with intermediate disease risk at diagnosis 
[18]. In the PIVOT trial, radical prostatectomy (n = 367) was compared with watchful waiting 
(n = 364) with a primary outcome of all-cause mortality and secondary outcomes of prostate 
specific mortality, metastases and symptoms in a largely screen-detected population. There 
was no difference in overall or disease-specific survival at a median of 10 years, but in a 
sub-group analysis men with a PSA of 10 ng/ml and above or intermediate risk disease had 
a survival advantage with surgery [19]. 
 
These two trials do, at least, provide some degree of proof of concept that definitive therapy 
might indeed cure, or at any rate prolong the survival of, some men with prostate cancer. 
However, both were surgical trials; there are no large trials comparing radical radiotherapy to 
watchful waiting or surgery for localised disease. Radiotherapy after surgery also conferred a 
clinical progression-free survival advantage in the EORTC 22911 trial over no additional 
treatment in men younger than 70 years and those with positive surgical margins with 
pathological T3 disease [20]. 
 
In locally advanced disease there are more data pertaining to radiotherapy. In the influential 
EORTC 22861 trial, men with predominantly locally advanced disease were randomised to 
radiotherapy, or to radiotherapy and hormone therapy [21]. Overall survival was substantially 
better in men treated additionally with hormone therapy, but what was the contribution of 
each? The SPCG-7 and intergroup MRC PR3/PR07 studies randomised men with 
predominantly localised (SPCG) or predominantly locally advanced (MRC) disease to 
hormone therapy alone, or to hormone therapy plus radiotherapy. In both trials, men who 
received radiotherapy had significantly better overall survival than men treated with hormone 
therapy alone [3,22]. Thus, at least in the context of locally advanced disease, radical 
radiotherapy prolongs survival and conceivably might cure some men. ProtecT is, however, 
the only prostate cancer trial in the modern era which compares radiotherapy, surgery and 
active monitoring - the latter permitting deferred radical therapy, and is almost the only trial 
comparing surgery and radiotherapy. The two previous randomised trials of surgery versus 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
radiotherapy in localised or locally advanced disease failed to answer the question as they 
were too small, and the radiotherapy techniques would be considered suboptimal today 
[23,24], whilst a further Swedish trial of radiotherapy versus watchful waiting only published 
quality of life outcomes [25].  
 
 
The impact of dose escalation and the introduction 
of quality assurance into UK clinical trials 
 
With the advent of dose escalation came an absolute requirement for ensuring that 
radiotherapy was meticulously planned according to pre-defined criteria and consistently 
delivered. This might be taken for granted now, but it was far from self-evident at the time 
when the RT01 and ProtecT trials were in design. Across the UK there was wide variation in 
institutional dose and fractionation [26,27]; there were no standard criteria defining prostate 
volumes, treatment margins, or the sparing of critical normal tissues. Formal quality 
assurance programmes had been introduced into several of the randomised trials of dose 
escalation worldwide, but in the UK, the RT01 trial was the first of its kind that had an 
integrated, formal process of quality assurance [28]. In that trial, prostate volumes were pre-
defined (Table 1), and planning margins were similarly defined after categorising patients 
according to their risk of seminal vesicles involvement, using an algorithm developed by the 
RTOG [29]. In the ProtecT study, a similar approach was adopted (Table 1) but with 
specified rectal and bladder dose constraints.  
 
 
A quality assurance programme with interlinked components was established in both 
ProtecT and RT01 trials. An early process in both trials was that all clinical centres were 
visited, and machine quality measured using phantom and other dosimetry [30]. No 
significant adverse findings were reported from these assessments in the RT01 study (mean 
dose difference -2%) [31] or the ProtecT study where the mean error in prediction from 
planned ranged from -4.4% to 0.2% across nine centres (Figure 1).  
 
In the RT01 study, an outlining exercise was performed by each centre with three practice 
cases, and the results of patient outlining were assessed both prospectively and 
retrospectively [32]. In the ProtecT study, recruitment started in three pilot centres in 1999 
and increased to nine centres between 2002 to 2004. Consequently, as outlining exercises 
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had already been completed by all but one study centre for either or both of the RT01 and 
CHHIP studies (which recruited between 2002-2006), the focus of the on-trial outlining was 
through discussions of issues at ProtecT radiotherapy meetings with clinical centres. 
Subsequently, outlining was retrospectively reviewed by two radiotherapists (JNS and 
MDM). Three patients from the ‘low' and three from the 'moderate' risk group were randomly 
selected for each centre to represent a total of around 10% of patients randomised to 
radiotherapy (n = 545). Their CT and outlining data were visualised using the CERR 
(Computational Environment for Radiotherapy Research) software [33].   
 
Outlining was assessed against criteria in the ProtecT protocol. Outlines were classified 
according to whether they were satisfactory, "acceptable" (a deviation from the protocol, but 
acceptable clinical practice), or "unacceptable" (a protocol deviation with potential clinical 
consequences) and the results are summarised in Table 2. The PTV margins have no errors 
in outlining in the 108 cases reviewed (two volumes/case). There were some variations from 
the protocol; however, only three (1.4%) were assessed as potentially being of clinical 
significance. Two examples of protocol violations in outlining are shown in Figure 2. These 
were all related to poor outlining of the prostate (Figure 2a), possibly due to insufficient 
radiological anatomy knowledge or drawing target volumes as this was published in the mid-
1990s and may have affected the pilot cases. The majority (15/23, 65%) of acceptable 
protocol variations were related to incorrect definition of the seminal vesicles and the 
majority of these (10/16, 63%) were in the definition of the base of the seminal vesicles 
(Figure 2b). We hypothesise that this relates to the concurrent recruitment to the RT01, 
CHHiP and ProtecT trials in centres as each trial had different definitions of the volume of 
seminal vesicles to be included in the base. This issue was not highlighted to clinical 
investigators at that time.  
 
In the RT01 study, although a prospective outlining exercise was performed, the first of its 
kind in a UK clinical trial [32], there was no possibility for assessment of adherence to pre-
specified dose constraints in organs at risk. In the ProtecT study, adherence to 13 dose 
constraints, including the bladder (2) and rectum (5), the main organ at risk for treatment 
toxicity, were assessed by an independent radiotherapy physicist in the same cases 
selected for outline review, and the results are summarised in Figure 3. Many deviations 
were driven by clinical necessity, e.g. an unfavourable anatomy. Around 80% of the plans 
had two or fewer deviations so this was judged to show good overall adherence to the trial 
protocol. PTV1 coverage was fully met for 89% (46) of plans, with a further three between 
95.8% and 98.0% and in the remaining three the dose was reduced probably for clinical 
reasons. Similar results were obtained for PTV2. 
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The quality of radiotherapy planning and delivery was judged to be satisfactory in both RT01 
and ProtecT trials. Deviation from the protocol has the potential to confound the study 
question and so quality assurance is, therefore, essential when comparing different 
treatments and trials. Our analysis of a subset of the radiotherapy plans demonstrates good 
understanding and adherence to the ProtecT protocol. Since then, pre-specified QA has 
become a requisite component, and of recent UK prostate trials, the most detailed 
programme is in the CHHIP study with single phase forward planned three-field IMRT [4].  
 
An outside observer might reasonably (though provocatively) ask; what has QA achieved in 
this setting? After all, some notable trials identified benefits for radiotherapy (RT) with QA 
features of their era (e.g. EORTC 2291 or EORTC 22863) sometimes without pre-specified 
constraints to organs at risk or with outlining reviews conducted retrospectively [2, 20,34]. 
The answer is twofold. Firstly, a common feature of these studies is that they were variations 
on a theme of "RT versus no RT"; modern radiotherapy trials either compare radiotherapy 
with another equivalent modality (ProtecT), or different techniques, doses, or schedules (e.g. 
RT01 and CHHIP) or the non-randomised comparisons recently published from the 
STAMPEDE trial [35]. As the trend moves inexorably towards higher total dose equivalents, 
and fewer fractions [4], the desirability of highest quality treatment delivery becomes an 
absolute imperative - with much to lose in terms of adverse effects for patients otherwise.  
 
 
The worldwide perspective and QA implementation 
in future trials  
 
Worldwide support for QA within radiotherapy trials has differed considerably. The US, via 
the Radiation Therapy Oncology Group (RTOG), has, with central funding, had formal QA 
programmes since the 1970’s for clinical trials employing radiotherapy with detailed 
credentialing for trial centres for IMRT trials [36]. Funding from RTOG has allowed on-trial 
review and analysis of trial outcomes against levels of protocol adherence which has 
historically been beyond our scope in the UK. The EORTC Radiotherapy Group has also 
had a comprehensive QA programme since the 1980’s with centralised support and 
infrastructure for radiotherapy trials [37]. In due course it might be possible to analyse 
treatment failures in relation to the quality of treatment delivery, and ProtecT could be an 
exemplar when outcome data are available in 2016.  
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A second key benefit of retrospective analysis of trial QA is learning for the future. It is now 
clear that groups setting up multiple trials in the same tumour site should aim to minimise 
differences in radiotherapy techniques between the trials. This has been an ongoing effort 
within the UK’s NCRI RadioTherapy Trials Quality Assurance group with notable successes 
across trials from different trial groups in rectal, oesophageal and pancreatic cancer trials 
[38]. However, there are still exceptions especially with large international collaborative trials 
which have detiailed QA programmes but they are not standardised with other trials within a 
country (e.g. PACE [39]:).  
 
 
Future Prospects - ProtecT and its impact 
 
An inherent feature of any technology-dependent study is that its technique will become 
obsolete. That will happen for today's sophisticated studies of IMRT and IGRT as surely as it 
did for conventional isocentrically planned radiotherapy. There is no doubt that, were trials 
such as ProtecT to be launched today, the QA programme would look very different to the 
way in which it was actually done. Will this impact on the interpretation of the ProtecT 
results, when they are finally released? It is essential that the standards of treatment 
delivery, whether surgery, radiotherapy (or indeed, active monitoring) are presented clearly 
and judged by the standards of their time. Against those standards it would seem that the 
radiotherapy delivery in trials such as ProtecT and RT01 was, at the very least, satisfactory, 
and will not be a confounding factor when comparisons are made between the three ProtecT 
treatments for clinical and patient-reported outcomes. How those findings are then related to 
modern techniques, or to other modalities such as focal therapy, SBRT, or brachytherapy, is 
a matter for future discussion, but those discussions will undoubtedly be better informed by 
quality assurance having been embedded in the ProtecT trial. 
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Table 1: Target volumes, treatment margins and dose constraints in the RT01 and 
ProtecT protocols 
 
 
Parameter RT01 (74 Gy arm) ProtecT 
Risk category Roach formula (Low & 
Moderate risk groups) 
Roach formula (Low & Moderate risk groups) 
Phase I CTV Prostate and base SV + 
0.5 mm (L) or SV (M) 
Prostate & base SV (L) or SV (M),  
Constraint: no margin beyond organ 
Phase I PTV CTV1 + 5-10 mm CTV1 + 10 mm 
Phase II CTV Prostate Prostate, Constraint: no margin beyond organ 
Phase II PTV As per CTV CTV2 + 5 mm 
Phase I dose and fractionation 64 Gy in 32# 56 Gy in 28# (PTV1 V95%, 53.2Gy) 
Phase II dose and fractionation 10 Gy in 5# 18 Gy in 9# (PTV2 V95%, 17.1Gy) 
Summed dose constraints  
 
Unique gantry angles  3 or 4 
  ICRU max D1.8cc ≤105% (77.7 Gy) 
Bladder Not to exceed prescribed 
dose to isocentre V74Gy <25% 
  V67Gy <50% 
Rectum None specified V74Gy ≤3% 
  V70Gy <25% 
  V67Gy <30% 
  V55.5Gy <50% 
  Minimum AP separation of 44Gy isodose and 
posterior rectal contour along midline >0 mm 
Femoral heads None specified D2cc <55Gy left and right 
 
  
Table
Table 2: Retrospective outlining assessment in the ProtecT trial 
 
Target volume 
(number assessed) 
 
Prostate 
(54) 
Seminal 
vesicles 
(54) 
Bladder 
(54) 
Rectum 
(54) 
Total 
(216) 
Percentage 
(%) 
Satisfactory 40 35 53 40 168 77.8% 
Acceptable variation 2 15 1 4 22 10.2% 
Unacceptable variation 
Clinical significance: 
  Unlikely 
 
 
9 
 
 
4 
 
 
0 
 
 
10 
 
 
23 
 
 
10.6% 
  Possible 3 0 0 0 3 1.4% 
Total 54 54 54 54 216 100% 
 
Figure 1: Phantom dosimetry results from the nine ProtecT centres 
 
 
 
 
The planned dose normalised for an error-free planning system and setup with negligible 
measurement error is plotted against actual dose by centre (1-9) measured using an 
anthropometric phantom. Doses at seven points around the prostate and irradiated volumes 
were predicted (using the centre system) and measured for both phases. 
  
Illustrations
Figure 2 Examples of protocol variations in outlining in the ProtecT trial 
 
 
 
CT slices from two volumes drawn by clinicians from two centres to illustrate protocol 
variations of potentially clinical significance. (a) The investigator has not outlined any CTV on 
this slice. The reviewers opinion of the correct CTVprostate is shown in blue, this protocol 
variation was viewed to be a potentially clinically significant error. The investigator 
CTVseminal vesicles outline is shown in purple (marked with arrow). The reviewers 
CTVseminal vesicle outline is shown in light green; this was classified as a clinical error, but 
was felt unlikely to have clinical consequences. (b) Investigator outline of CTVseminal 
vesicles (light green, marked with arrow) does not encompass all the seminal vesicles 
whereas the reviewers outline of the seminal vesicles is shown in the dark blue line, this 
protocol variation was viewed as a clinical error, but unlikely to have clinical significance. 
  
Figure 3. Compliance with rectal, bladder, femoral heads and PTV dose constraints in 
the ProtecT trial 
 
 
Two plans from one centre did not have dose data so were excluded from the total 54 plans. 
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